Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | PTPRB | P23467 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257928 | 0.80 | SMPD1 (0.37) | — | |
| SCHEMBL6259130 | 0.77 | SMPD1 (0.39) | S1PR1S1PR3S1PR4S1PR2TSHR | |
| SCHEMBL6719162 | 0.75 | SMPD1 (0.34) | — | |
| SCHEMBL7161851 | 0.72 | SMPD1 (0.33) | — | |
| SCHEMBL6258960 | 0.72 | PTPN2 (0.40) | PTPN2PTPN1PTPN6TSHRALDH1A1 | |
| SCHEMBL6345298 | 0.72 | LMNA (0.38) | S1PR1S1PR3S1PR4S1PR2ALDH1A1 | |
| SCHEMBL5362490 | 0.72 | S1PR2 (0.38) | S1PR1S1PR3S1PR4S1PR2L3MBTL1 | |
| SCHEMBL22667771 | 0.72 | TSHR (0.39) | PTPN2PTPN1PTPN6TSHRL3MBTL1 | |
| SCHEMBL6344406 | 0.71 | CA2 (0.43) | S1PR1S1PR3S1PR4S1PR2ALDH1A1 | |
| SCHEMBL13053745 | 0.71 | S1PR1 (0.37) | S1PR1S1PR3S1PR4S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| JP-2004529069-A | — | — | 2004-09-24 | — | — | JP | claimed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6713507-B2 | CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; ALZHEIMER'S DISEASE | ESPERION THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | PTPN2 903/4885PTPN1 681/4885PTPN6 804/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | PTPN2 903/4885PTPN1 681/4885PTPN6 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.